All In Biotech

Drug Trial Radar · NCT07906106

A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)

Multi-center, Double-blind, Randomized, Placebo-controlled Proof-of-concept (POC) Study of SFG-02 Transdermal Drug Delivery System Formulation in Participants With Underactive Bladder

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 22, 2026

Primary completion

Feb 28, 2028

Study completion May 31, 2028

Sponsor

Lead sponsor
Juro Sciences Inc.Industry
Sponsor type
Industry
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB. Participants will: * Apply the study patches every day for 12 weeks and wear each patch for a full day * Visit the clinic once every 2 to 4 weeks for checkups and tests * Keep diaries about their bladder symptoms and the times they change their study patches

Conditions

  • Participants With Underactive Bladder (UAB)

Interventions

  • SFG-02Drug

    Transdermal formulation containing SFG-02 1.6 mg once a day

  • PlaceboDrug

    placebo once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bladder Voiding Efficiency (BVE)Time frame: The change from Baseline (Week 4) to Week 12

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site selected by Juro

    Fukuoka, Japan · Recruiting

  • Clinical Site selected by Juro

    Fukushima, Japan · Recruiting

  • Clinical Site selected by Juro

    Kumamoto, Japan · Recruiting

  • Clinical Site selected by Juro

    Nagasaki, Japan · Recruiting

  • Clinical Site selected by Juro

    Saga, Japan · Recruiting

  • Clinical Site selected by Juro

    Shizuoka, Japan · Recruiting

  • Clinical Site selected by Juro

    Nagoya, Aichi-ken, Japan · Recruiting

  • Clinical Site selected by Juro

    Ōbu, Aichi-ken, Japan · Recruiting

  • Clinical Site selected by Juro

    Katori-shi, Chiba, Japan · Recruiting

  • Clinical Site selected by Juro

    Yoshida-gun, Fukui, Japan · Recruiting

  • Clinical Site selected by Juro

    Sapporo, Hokkaido, Japan · Recruiting

  • Clinical Site selected by Juro

    Mito, Ibaraki, Japan · Recruiting

  • Clinical Site selected by Juro

    Chiyoda-ku, Tokyo, Japan · Recruiting

  • Clinical Site selected by Juro

    Meguro-ku, Tokyo, Japan · Recruiting

  • Clinical Site selected by Juro

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • Clinical Site selected by Juro

    Chūō, Yamanashi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.